Literature DB >> 12019159

Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk.

David P Miller1, Geoffrey Liu, Immaculata De Vivo, Thomas J Lynch, John C Wain, Li Su, David C Christiani.   

Abstract

GSTP1 and GSTM1 are genes involved in Phase II metabolism, whereas p53 is a tumor suppressor gene. Individually, functional polymorphisms of these genes have been studied as risk factors for lung cancer. Small sample sizes have hindered the detection of possible increases in risk associated with having two or more "at risk" polymorphisms of these three genes. In a large Caucasian population, we examined the association of combined variant genotypes [or double-variants (DVs)] of these three genes and lung cancer risk, compared with their corresponding "double-wild-type" genotypes. Because these DVs may promote lung carcinogenesis at an earlier age, a subgroup of individuals aged 55 years or younger was examined separately. Using a case-control design, individuals were genotyped for GSTM1, GSTP1, and p53 codon 72 using PCR-RFLP techniques. All of the analyses used multiple logistic regression. Indicator variables were created to evaluate the risk for individuals with the following DVs: GSTP1 GG + GSTM1-null and GSTP1 GG + p53 Arg/Pro or Pro/Pro. A total of 1694 cases and controls were evaluated. In the whole population, those with the double variants have a higher risk of lung cancer when compared with those with the double-wild-type genotypes, supporting our original hypothesis. Individuals with the GSTP1 and GSTM1, DV (P1-M1 DV) had a marginally significant higher risk of lung cancer compared with their double-wild-type counterparts [adjusted odds ratio (AOR), 1.60; 95% confidence interval (CI), 0.95-2.70]. A significantly higher risk was found for the GSTP1, p53 DV (P1-p53 DV; AOR, 1.99; 95% CI, 1.12-3.53). Among individuals aged 55 or younger, these risks were even higher: for the P1-M1 DV the AOR was 4.03 (95% CI, 1.47-11.1); for the P1-p53 DV the AOR was 5.10 (95% CI, 1.42-18.30). Specific DVs of GSTM1, GSTP1, and p53 codon 72 are associated with a higher lung cancer risk. This susceptibility is highest among younger individuals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019159

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  A Large-scale genetic association study of esophageal adenocarcinoma risk.

Authors:  Chen-Yu Liu; Michael C Wu; Feng Chen; Monica Ter-Minassian; Kofi Asomaning; Rihong Zhai; Zhaoxi Wang; Li Su; Rebecca S Heist; Matthew H Kulke; Xihong Lin; Geoffrey Liu; David C Christiani
Journal:  Carcinogenesis       Date:  2010-05-07       Impact factor: 4.944

2.  A weighting approach to causal effects and additive interaction in case-control studies: marginal structural linear odds models.

Authors:  Tyler J VanderWeele; Stijn Vansteelandt
Journal:  Am J Epidemiol       Date:  2011-10-19       Impact factor: 4.897

3.  Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction.

Authors:  Tyler J VanderWeele; Kofi Asomaning; Eric J Tchetgen Tchetgen; Younghun Han; Margaret R Spitz; Sanjay Shete; Xifeng Wu; Valerie Gaborieau; Ying Wang; John McLaughlin; Rayjean J Hung; Paul Brennan; Christopher I Amos; David C Christiani; Xihong Lin
Journal:  Am J Epidemiol       Date:  2012-02-03       Impact factor: 4.897

4.  Association between GSTM1, GSTT1, and GSTP1 polymorphisms and lung cancer risk in a Turkish population.

Authors:  Ahmet O Ada; Semih C Kunak; Figen Hancer; Emre Soydas; Sibel Alpar; Meral Gulhan; Mumtaz Iscan
Journal:  Mol Biol Rep       Date:  2011-12-30       Impact factor: 2.316

5.  Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.

Authors:  Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

6.  Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study.

Authors:  M L Cote; A S Wenzlaff; C H Bock; S J Land; S K Santer; D R Schwartz; A G Schwartz
Journal:  Lung Cancer       Date:  2006-12-15       Impact factor: 5.705

7.  The sociobiologic integrative model (SBIM): enhancing the integration of sociobehavioral, environmental, and biomolecular knowledge in urban health and disparities research.

Authors:  M Chris Gibbons; Malcolm Brock; Anthony J Alberg; Thomas Glass; Thomas A LaVeist; Stephen Baylin; David Levine; C Earl Fox
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

8.  Modifying roles of glutathione S-transferase polymorphisms on the association between cumulative lead exposure and cognitive function.

Authors:  Ki-Do Eum; Florence T Wang; Joel Schwartz; Craig P Hersh; Karl Kelsey; Robert O Wright; Avron Spiro; David Sparrow; Howard Hu; Marc G Weisskopf
Journal:  Neurotoxicology       Date:  2013-08-16       Impact factor: 4.294

9.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

10.  Association study of SNPs of genes IFNGR1 (rs137854905), GSTT1 (rs71748309), and GSTP1 (rs1695) in gastric cancer development in samples of patient in the northern and northeastern Brazil.

Authors:  Rubistenia Miranda Soares de Araújo; Cynthia Farias Vieira de Melo; Fidelis Manes Neto; Juarez Nóbrega da Silva; Leonardo Ferreira Soares; Marilia de Arruda Cardoso Smith; Edilson Carvalho Sousa; Rommel Mario Rodríguez Burbano; Arnaldo Correia de Medeiros; Eleonidas Moura Lima
Journal:  Tumour Biol       Date:  2014-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.